AMGN•benzinga•
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Summary
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 9, 2025 by benzinga